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Abstract: Background: The use of radiolabeled prostate-specific membrane antigen positron emission
tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer
(BRPCa) is increasing worldwide. Recently, 18F-labeled PSMA agents have become available. We
performed a systematic review and meta-analysis regarding the detection rate (DR) of 18F-labeled
PSMA PET/CT in BRPCa to provide evidence-based data in this setting. Methods: A comprehensive
literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases through 23 April
2019 was performed. Pooled DR was calculated on a per-patient basis, with pooled proportion and
95% confidence interval (95% CI). Furthermore, pooled DR of 18F-PSMA PET/CT using different
cut-off values of prostate-specific antigen (PSA) was obtained. Results: Six articles (645 patients)
were included in the meta-analysis. The pooled DR of 18F-labeled PSMA PET/CT in BRPCa was
81% (95% CI: 71–88%). The pooled DR was 86% for PSA ≥ 0.5 ng/mL (95% CI: 78–93%) and 49% for
PSA < 0.5 ng/mL (95% CI: 23–74%). Statistical heterogeneity was found. Conclusions: 18F-labeled
PSMA PET/CT demonstrated a good DR in BRPCa. DR of 18F-labeled PSMA PET/CT is related to
PSA values with significant lower DR in patients with PSA < 0.5 ng/mL. Prospective multicentric
trials are needed to confirm these findings.
Keywords: PET; PSMA; prostate; DCFPyL; DCFBC; PSMA-1007
1. Introduction
The recent development of metabolic imaging methods has been aimed at improving diagnosis
of prostate cancer (PCa), both at staging and in biochemical recurrent prostate cancer (BRPCa) when
an increase of prostate-specific antigen (PSA) serum values is detected following curative primary
treatments as radical prostatectomy or radiation therapy [1,2]. In patients with low but rising PSA
serum values after definitive local therapy, it is important to identify the sites of recurrence early
to maximize the effects of treatment; localizing the PCa recurrence can impact treatment decisions
as local recurrence can be treated with focal radiation therapy, whereas distant metastases require
more systemic therapies [1]. To this regard, radiolabeled prostate-specific membrane antigen (PSMA)
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positron emission tomography/computed tomography (PET/CT) is emerging as a very useful imaging
method for detecting tumor lesions in BRPCa patients, with higher DR compared to other imaging
modalities [1–5].
The PSMA is overexpressed in the majority of PCa cells but its overexpression has not been found
in benign prostatic diseases; however, PSMA is not prostate specific and this protein may be expressed
in other tissues and tumors beyond PCa [3–5].
Several PSMA ligands, differing slightly in chemical structure, are commercially available and they
may be radiolabeled with different positron-emitters isotopes as Gallium-68 (68Ga), Fluorine-18 (18F),
or Copper-64 (64Cu) to obtain PET radiopharmaceuticals which could be used in clinical practice [4–8].
68Ga-labeled PSMA tracers are currently the most used PSMA agents for PET imaging of BRPCa
patients. More recently, PSMA ligands had been labeled with other isotopes with more favorable
physical characteristics, such as 18F or 64Cu [6–8]. Several 18F-labeled PSMA agents have become
available (18F-PSMA-1007, 18F-DCFPyL, and 18F-DCFBC). Labeling of PSMA agents with 18F may
offer numerous advantages, including longer half-life and improved image resolution. Due to the
lower positron energy, the theoretical achievable resolution of 18F is slightly better in comparison to
68Ga [7,8]. To date, several evidence-based articles evaluated the detection rate (DR) of 68Ga-labeled
PSMA PET/CT in BRPCa patients [9–15]. Conversely, we aimed to perform a meta-analysis about the
DR of 18F-labeled PSMA PET/CT in BRPCa patients to add evidence-based data in this setting.
2. Methods
Reporting of this systematic review and meta-analysis conforms to the “Preferred Reporting
Items for a Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies” (PRISMA-DTA
statement) which describes an evidence-based minimum set of items for reporting in systematic
reviews and meta-analyses of diagnostic studies [16,17].
2.1. Search Strategy
Three authors (G.T., S.A., D.A.P.) performed a comprehensive computer literature search of
PubMed/MEDLINE, EMBASE and Cochrane library databases to find relevant published articles on
the DR of PET/CT using 18F-labeled PSMA-agents in patients with BRPCa.
A search algorithm based on a combination of these terms was used: (A) “PSMA” AND (B)
“DCFPyL” OR “DCFBC” OR “1007”. No beginning date limit and language restrictions were used, and
the literature search was updated until 23 April 2019. To expand our search, references of the retrieved
articles were also screened for additional studies.
2.2. Study Selection
Studies or subsets of studies investigating the DR of 18F-labeled PSMA PET/CT in patients with
BRPCa were eligible for inclusion in the qualitative (systematic review) and quantitative analysis
(meta-analysis). The exclusion criteria for the systematic review were: (a) articles not within the field
of interest of this review; (b) review articles, editorials or letters, comments, conference proceedings; (c)
case reports or small case series. For the meta-analysis, articles with possible patient data overlap were
excluded; in this case, articles with more complete information were included in the meta-analysis.
Titles and abstracts were independently reviewed by three researchers applying the selected
inclusion and exclusion criteria. Disagreements were solved in a consensus meeting.
2.3. Data Extraction
For each eligible article, information was collected concerning basic study (authors, year of
publication, country of origin, study design), patient characteristics (type and number of patients
evaluated, mean age, Gleason score, mean/median PSA serum values, and PSA doubling time before
18F-PSMA PET/CT), technical aspects (radiotracer used, hybrid imaging modality, mean radiotracer
injected activity, time interval between radiotracer injection and image acquisition, image analysis
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and other imaging modalities performed for comparison). For articles included in the meta-analysis,
information was collected about DR values of 18F-PSMA PET/CT (overall and at different PSA cut-off
values) on a per patient-based analysis, mean PSA serum values in patients with positive and negative
18F-PSMA PET/CT, percentage of change of management by using 18F-PSMA PET/CT in BRPCa.
2.4. Quality Assessment
The overall quality of the studies included in the meta-analysis was critically appraised based on
the revised “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2) [18]. This tool
comprises four domains (patient selection, index test, reference standard, and flow and timing) and
each domain was assessed in terms of risk of bias, and the first three domains were also assessed in
terms of concerns regarding applicability [18].
2.5. Statistical Analysis
The DR of 18F-PSMA PSMA PET/CT was defined as the ratio between the number of patients
with at least one suspected lesion detected by PET/CT and the total number of BRPCa patients who
underwent the scan. Pooled analyses about DR of 18F-PSMA PET/CT were performed using data
retrieved from the selected studies and subgroup analyses taking into account different PSA serum
values or different radiotracers were planned. Furthermore, a pooled analysis about the mean difference
of PSA serum values in patients with positive and negative 18F-PSMA PET/CT was carried out.
A random-effects model was used for statistical pooling of the data, taking into account the
heterogeneity between studies. The different weight of each study in the pooled analysis was related to
the different sample size. Pooled data were presented with their respective 95% confidence interval (95%
CI) values, and data were displayed using plots. Heterogeneity was estimated using the I-square index
(I2), which describes the percentage of variation across studies that was due to the heterogeneity rather
than chance [19], whereas the publication bias was assessed through the Egger’s test [20]. Statistical
analyses were performed using the StatsDirect software version 3 (StatsDirect Ltd., Cambridge, UK).
3. Results
3.1. Literature Search
Literature search results are reported in Figure 1.
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Table 1. Basic study and patient characteristics.
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Legend: BRPCa = biochemical recurrent prostate cancer; ADT = androgen deprivation therapy; NA = not available; PET = positron emission tomography; PSA = prostate-specific antigen;
PSMA = prostate specific membrane antigen; RP = radical prostatectomy; RT = radiation therapy.
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Table 2. Technical aspects of 18F-PSMA PET/CT in the included studies.













Giesel et al. [29] 18F-PSMA-1007 PET/CT with low-dose CT NR
301 ± 46 (154–453)
MBq 92 ± 26 min visual -
Rousseau et al. [28] 18F-DCFPyL PET/CT with low-dose CT yes (at least 4 h)
369.2 ± 47.2
(237–474) MBq 120 min
visual and semi-quantitative
(SUVmax, SUVpeak, SUL, TLG,
SUVratio)
-
Rahbar et al. [27] 18F-PSMA-1007
PET/CT with low-dose or
contrast enhanced CT NR
338 ± 44.31 MBq




Giesel et al. [26] 18F-PSMA-1007 PET/CT with low-dose CT NR
251.5 (154–326)




Rahbar et al. [25] 18F-PSMA-1007
PET/CT with low-dose or
contrast enhanced CT NR
336.7 ± 46 MBq




Mena et al. [24] 18F-DCFBC PET/CT with low-dose CT NR
292.3 (255.3–299.7)




Wondergem et al. [23] 18F-DCFPyL
PET/CT with contrast














Legend: MBq = MegaBecquerel; mpMRI = multi-parametric magnetic resonance imaging; NR = not reported; PET/CT = positron emission tomography/computed tomography; SUL = lean
body mass standardized uptake value; SUVmax = maximal standardized uptake value; SUVpeak = peak standardized uptake value; SUVratio = lesion to background uptake ratio; TLG =
total lesion glycolysis.
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Table 3. Main findings of the included studies about 18F-PSMA PET/CT in patients with biochemical recurrence of prostate cancer.
Authors



































Giesel et al. [29] 204/251 (81.3%) 40/65 (61.5%) 164/186 (88.2%) 35/47 (74.5%) 50/55 (90.1%) 79/84 (94%) 6.8 ± 22.4 0.95 ± 1.56 NR
Rousseau et al. [28] 110/130 (84.6%) 3/5 (60%) 107/125 (85.6%) 18/23 (78.3) 18/25 (72%) 71/77 (92.2%) 5.8 ± 6.87 1.86 ± 1.62 87%
Rahbar et al. [27] 95/100 (95%) 18/21 (85.7%) 77/79 (97.5%) 16/18 (88.9%) 22/22 (100%) 39/39 (100%) NR NR NR
Mena et al. [24] 41/68 (60.3%) 2/13 (15.4%) 39/55(70.9%) 6/13 (46.2%) 10/12 (83.3%) 23/30 (76.7%) 6.6 ± 8.89 1.22 ± 1.37 50%
Wondergem et al. [23] 28/34 (77.8%) NR NR NR NR NR NR NR NR
Dietlein et al. [22] 46/62 (74.2%) 1/8 (12.5%) 45/54 (83.3%) NR NR NR NR NR NR
Pooled values (95%
confidence interval) 81% (71–88) 49% (23–74) 86% (78–93) 73% (59–85) 88% (73–97) 92% (83–98)
Weighted mean PSA difference: 4.5
(3.3–5.7) -
I2 86% 83% 82% 54% 72% 77% 0% -
Legend: DR = detection rate on a patient-based analysis; I2 = inconsistency index; NR = not reported; PSA = prostate-specific antigen.
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3.2. ualitative nalysis (Syste atic Revie )
3.2.1. Basic Study and Patient Characteristics
Nine articles evaluating the DR of 18F-PSMA PET/CT in BRPCa patients were selected (Table 1) [21–
29]. The selected articles were published in the last five years by researchers from Europe and America;
only two out of nine studies were prospective studies (22%). Mean and median age of the patients
included in these studies ranged from 64 to 70 years. The Gleason score was 7 in 43–56%, ≤6 in 5–13%,
and ≥8 in 28–42% of cases. Mean and median PSA serum values before PET/CT among the included
BRPCa patients ranged from 0.6 to 5.2 ng/mL.
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3.2.2. Technical Aspects
Technical aspects of the included studies are reported in Table 2. The 18F-labeled PSMA agent
used was 18F-PSMA-1007 in four studies, 18F-DCFPyL in four studies, and 18F-DCFBC in one study
only. The hybrid imaging modality was always PET/CT, mainly performed without CT contrast media
injection. The injected radiopharmaceutical activity and the time between radiotracer injection and
image acquisition were quite heterogeneous; in four studies a dual time point PET/CT imaging was
performed. Analysis of PET images was performed using qualitative criteria (visual analysis) in all the
studies and additional semi-quantitative criteria, i.e., calculating the maximal standardized uptake
values (SUVmax), in most of the studies. Areas of increased radiopharmaceutical uptake greater than
the surrounding tissue that could not be explained by physiological activity were judged as positive
findings at visual analysis. A clear reference standard was not specified in the included studies.
3.2.3. Main Findings
Most of the included studies demonstrated a good DR of 18F-PSMA PET/CT in BRPCa patients
which was dependent on PSA serum values: the proportion of positive scans increased with PSA
levels [21–29]. Conversely, no significant correlation between PSA doubling time and DR of 18F-PSMA
PET/CT was found [24]. The higher DR values were obtained using 18F-PSMA-1007 or 18F-DCFPyL as
radiotracers (Table 3).
Most frequent sites of lesions detected by 18F-PSMA PET/CT in BRPCa were regional and distant
lymph nodal metastases, local relapse, and bone metastases [21–29].
In three studies, a statistically significant difference of PSA serum values in patients with positive
18F-PSMA PET/CT compared to patients with negative 18F-PSMA PET/CT was found, but with a large
overlap in PSA values across these two categories [24,28,29].
In studies performing a dual time point 18F-PSMA PET/CT, a significant increased lesion uptake
and higher lesion-to-background uptake ratios were observed at a second time point (120 or 180 min
after radiotracer injection) compared to the first time point (60 min after radiotracer injection) [23–26].
No significant adverse effects of 18F-PSMA PET/CT were reported [21,24,27–29]. The change of
management by using 18F-PSMA PET/CT in BRPCa ranged from 50 to 87% of cases [24,28].
Two articles compared the DR of 18F-DCFPyL PET/CT with 18Ga-PSMA-11 PET/CT in BRPCa
patients. The 18F-DCFPyL PET/CT detected additional lesions compared to 18Ga-PSMA-11 PET/CT
(in particular for PSA values between 0.5 and 3.5 ng/mL) and the mean SUVmax of 18F-DCFPyL
PSMA-positive lesions was significantly higher as compared to 18Ga-PSMA-11 positive lesions [21,22].
Several discordant findings were found when 18F-PSMA PET/CT was compared to
multi-parametric MRI, demonstrating the complementary role of these imaging methods in BRPCa
patients [24].
3.3. Quantitative Analysis (Meta-Analysis)
Six studies (645 BRPCa patients) were selected for the pooled analysis [22–24,27–29]. The overall
DR of 18F-PSMA PET/CT on a per patient-based analysis ranged from 60% to 95%, with a pooled value
of 81% (95% CI: 71–88%) (Figure 3 and Table 3). We have detected a significant heterogeneity among
the selected studies (I2 = 86%), whereas a publication bias was not revealed (p = 0.16).
Performing a sub-group analysis taking into account different PSA cut-off values (Table 3 and
Figure 4), we found a statistical significant difference in DR of 18F-PSMA PET/CT in BRPCa patients
with PSA ≥ 0.5 ng/mL (pooled DR: 86%; 95% CI: 78–93%) compared to patients with PSA < 0.5 ng/mL
(pooled DR: 49%; 95% CI: 23–74%).
Performing a sub-group analysis taking into account different radiotracers, the pooled DR of
18F-PSMA-1007, 18F-DCFPyL, and 18F-DCFBC PET/CT were 89% (95% CI: 72–98%), 81% (95% CI:
74–87%) and 60% (95% CI: 48–72%), respectively.
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Weighted mean difference of PSA values among patients with positive 18F-PSMA PET/CT and
patients with negative 18F-PSMA PET/CT was 4.5 (95% CI: 3.3–5.7) without significant heterogeneity
(I2 = 0%).
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4. Discussion
Recently, some studies have evaluated the diagnostic performance of 18F-PSMA PET/CT in BRPCa
patients [21–29]; as these studies have limited power, due to the relatively small number of patients
enrolled and assessed, we have pooled data reported in published studies to derive more robust
estimates on the DR of 18F-PSMA PET/CT in this setting.
Overall, our systematic review and meta-analysis indicates a good DR of 18F-PSMA PET/CT in
BRPCa patients, in particular using 18F-PSMA-1007 and 18F-DCFPyL. The DR was dependent on PSA
serum values [21–29]: using the PSA cut-off of 0.5 ng/mL, the pooled DR of 18F-PSMA PET/CT was
86% in BRPCa patients with PSA ≥ 0.5 ng/mL and 49% in patients with PSA < 0.5 ng/mL. Therefore,
accurate timing of 18F-PSMA PET/CT, based on PSA values, substantially affects its diagnostic value
in BRPCa patients, and monitoring of PSA values could be useful for accurate timing of 18F-PSMA
PET/CT.
Beyond the PSA serum values, low PSMA expression (i.e., due to the tumor heterogeneity) might
cause false-negative 18F-PSMA PET/CT findings in some PCa patients [21–29]. About the pooled DR of
18F-PSMA PET/CT in BRPCa, we found similar results compared to those reported in the literature with
68Ga-labeled PSMA PET/CT [9–15]. Compared to PET/CT with 68Ga-labeled PSMA, the longer half-life
and higher injected activities of 18F-PSMA allow high-quality delayed images, higher lesion uptake,
and superior clearance of background activity [21–29]. Two studies only reported a comparison of
18F-PSMA and 68Ga-PSMA PET/CT in BRPCa patients with a trend towards a higher DR of 18F-PSMA
compared to 68Ga-PSMA PET/CT, but the acquisition protocols used in these studies included different
tracer uptake time periods for 18F-PSMA (120 min) and 68Ga-PSMA (60 min) before image acquisition
and different activity used for these radiopharmaceuticals (18F-PSMA > 68Ga-PSMA), which could
explain these results [21,22]. Assuming similar DR, the real additional value of 18F-PSMA tracers might
be the possibility of large-scale batch production in a cyclotron and satellite-center supply due to the
longer half-life [21–29].
As a significant increased 18F-PSMA uptake over time was demonstrated in PCa lesions with a
higher contrast at delayed PET/CT time points compared to early PET/CT time points [23–26], it is
not recommended to perform 18F-PSMA PET/CT at 60 min after radiotracer injection (which is the
common imaging time point for 68Ga-PSMA PET/CT). However, imaging at late time points may be a
logistic challenge for PET/CT centers.
Only two articles assessed the change of management that can be obtained by using 18F-PSMA
PET/CT in patients with BRPCa [24,28], reporting a significant change of management ranging from
50 to 87% of cases, in line with literature data about the change of management obtained by using
18Ga-PSMA PET/CT in this setting [30].
Some limitations and biases of our meta-analysis should be taken into account. First of all, a limited
number of studies were available for the meta-analysis. The major limitation of the included studies
was that not all positive PET/CT findings were confirmed by histology (verification bias). Confirmation
was impaired by the small volume of individual lesions and the high number of biopsy-inaccessible
lesions. In absence of histological validation, it cannot be excluded that some lesions detected by
18F-PSMA PET/CT may represent false-positive findings. Nevertheless, if modern imaging methods
are performed in BRPCa patients, then confirmation of positive findings are needed only in highly
selected cases and with a biopsy when findings are equivocal [1]. Even in the absence of histological
confirmation, clinical follow-up or decline of PSA after therapy can be helpful.
A possible limitation of our meta-analysis is the detected heterogeneity, likely due to the
different characteristics of patients, methods, and quality of included studies. We tried to explain
this heterogeneity performing sub-group analyses taking into account different PSA cut-off values
and different radiotracers. Some differences of DR were found using various 68F-PSMA agents, but
studies performing a head-to-head comparison of these tracers in BRPCa setting are not available yet.
We found a lower DR value using 18F-DCFBC compared with second-generation 68F-PSMA agents
(18F-PSMA-1007 and 18F-DCFPyL), likely because of the higher background signal of 18F-DCFBC
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due to the considerable blood-pool activity, which could limit the DR of pelvic and retroperitoneal
lymph node metastases [24]. In a recent pilot prospective study comparing 18F-PSMA-1007 and
18F-DCFPyL in the setting of PCa staging, similar DR were found using these radiopharmaceuticals [31].
Non-urinary excretion of 18F-PSMA-1007 might present some advantages with regard to delineation of
local recurrence or pelvic lymph node metastases in selected patients; the lower hepatic background
might favor 18F-DCFPyL in late stages, when rare cases of liver metastases can occur [31].
Diagnostic accuracy of a test is not a measure of clinical effectiveness and high DR values do
not necessarily result in improved patient outcomes. Other factors beyond the DR should influence
the choice of an imaging modality in patients with BRPCa (i.e., availability, radiation dose, safety,
examination time, legal, organization, economic aspects, and cost-effectiveness). Overall, our systematic
review and meta-analysis demonstrated a good DR of 18F-PSMA PET/CT in patients with BRPCa,
but large prospective multi-center studies, and in particular, cost-effectiveness analyses comparing
18F-PSMA to other PET radiopharmaceuticals are warranted.
5. Conclusions
•
18F-labeled PSMA PET/CT demonstrated a good DR in BRPCa, in particular using 18F-PSMA-1007
and 18F-DCFPyL, with similar results compared to those reported in the literature with 68Ga-labeled
PSMA PET/CT.
• The DR of 18F-labeled PSMA PET/CT is related to PSA values with significant lower DR in patients
with PSA < 0.5 ng/mL.
• Prospective multicentric trials are needed to confirm these findings; nevertheless, 18F-labeled
PSMA PET/CT seems to be a promising cost-effective alternative to 68Ga-labeled PSMA PET/CT
in BRPCa.
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